oteracil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| uracil type antineoplastics | 2002 | 937-13-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antagonist of urate oxidase.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 14, 2011 | EMA | Nordic Group BV |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Malignant tumor of stomach | indication | 363349007 | DOID:10534 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.67 | acidic |
| pKa2 | 10.06 | acidic |
| pKa3 | 0.5 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Uridine 5'-monophosphate synthase | Enzyme | INHIBITOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 2207-75-2 | SECONDARY_CAS_RN |
| C0030032 | UMLSCUI |
| CHEBI:80230 | CHEBI |
| OXC | PDB_CHEM_ID |
| CHEMBL181932 | ChEMBL_ID |
| DB03209 | DRUGBANK_ID |
| 4604 | PUBCHEM_CID |
| 7729 | INN_ID |
| C489337 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5VT6420TIG | UNII |
| 013265 | NDDF |
| 015260 | NDDF |
| D010094 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
None